Navigation Links
8-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar

Positive Results in Patients With Follicular Lymphoma Reported Today at ASCO Annual Meeting

PHILADELPHIA, June 04, 2007 /PRNewswire/ -- GlaxoSmithKline plc announced today long-term efficacy data from a Phase II trial of a single one-week course of frontline treatment with the BEXXAR(R) Therapeutic Regimen (Tositumomab and Iodine I-131 Tositumomab) in 76 patients with newly diagnosed advanced follicular non-Hodgkin's lymphoma (NHL). This regimen was found to induce durable clinical and molecular remissions in patients with this disease. Specifically, researchers reported that patients who received a single one-week treatment of BEXXAR as monotherapy achieved estimated 8-year and 10-year overall survival (OS) rates of 86%. Additionally, 50% of patients survived without progression of disease at 8 years following therapy. For patients who achieved complete remission, the median time before their disease progressed was 9.2 years. An overall response rate and complete remission rate of 95% and 75%, respectively, were observed. These data were presented today at the 2007 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois (Abstract #8033).(1)

"For years we have known that radioimmunotherapy, such as BEXXAR, is an effective treatment for patients with relapsed or refractory lymphoma. The data from this frontline study suggest that BEXXAR may also have activity when used as a frontline treatment and should be studied further in this setting. Of note, these results were achieved with BEXXAR given as a single treatment, completed within one week, which made it a convenient regimen for these patients," said Mark Kaminski, Professor of Internal Medicine and Director, Leukemia/Lymphoma Program at the University of Michigan and lead investigator of this study.

The five-year follow-up data from this study were originally reported in the New England Journal of Medicine (NEJM 352:441,
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
2. Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW
3. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
4. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
5. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
6. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
7. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
8. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
9. Nationwide MRSA Prevalence Study to Demonstrate Full Scope of Superbug Threat Facing U.S. Healthcare Facilities and Patients
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
Post Your Comments:
(Date:10/8/2008)... Reduce Animal Use in Cosmetics and Chemicals Test...k Corp. today announced,that results of a recently...-up" validation study on MatTek,s EpiDerm in vitro...monstrated the required sensitivity and,specificit...ative to animal,testing for determining human skin...
(Date:10/8/2008)...nstitute Pioneers Research That May Offer New Hope...wswire/ -- Nationally, over 3,000 people are,waiti...e. Sadly, only half,of those will receive a transp...stitute (AHI) is paving the way for how to treat c...the Multimedia News Release, go to:, http://www.pr...
(Date:10/8/2008)...rsity Food Scientists Expand Testing Using Cellula..., PORTLAND, Maine, Oct. 8 /- Wild Bl...he release of results from a new study,showing Wil...consumed,fruits like apples, bananas, red grapes a...ular Antioxidant Activity (CAA) assay. New researc...
(Date:10/8/2008)...Confirm Potency of Poly-ICR as Vaccine Adjuvant, ... Biopharmaceuticals,Corporation (TSX: NVN) today p...ing its proprietary Toll-like Receptor 3 agonist, ...cine Congress 2008 in Lyon, France.,Study results ...ant,targeting the Toll-like Receptor 3 (TLR3) path...
Breaking Medicine Technology:MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 3Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5Hurried doctor visits may leave patients feeling forgetful 22772 1Hurried doctor visits may leave patients feeling forgetful 22772 2Microsoft Announces Winners of the 2008 Pharmaceutical and Life Sciences Innovation Awards 22766 1Microsoft Announces Winners of the 2008 Pharmaceutical and Life Sciences Innovation Awards 22766 2Microsoft Announces Winners of the 2008 Pharmaceutical and Life Sciences Innovation Awards 22766 3Microsoft Announces Winners of the 2008 Pharmaceutical and Life Sciences Innovation Awards 22766 4Christine Poon Will Keynote MichBio Expo 6210 1Christine Poon Will Keynote MichBio Expo 6210 2Christine Poon Will Keynote MichBio Expo 6210 3 TraumaCure Receives Prestigious ISO 13485 Certification 6209 1 TraumaCure Receives Prestigious ISO 13485 Certification 6209 2
...d today shows reduction of 70,percent in spine fra...ER, N.J., May 02, 2007 /PRNewswire/ -- A once-year...tion significantly,reduced the incidence of all ty...s in women with postmenopausal osteoporosis. This,...of Medicine,marks the first time that an osteopor...
...- Bayer HealthCare,Pharmaceuticals announced today...ron(R) (interferon beta-1b), presented this week,a...nnual Meeting,demonstrating early efficacy, long-...ith treatment in patients with relapsing,forms of ...udies highlight the important clinical,benefits an...
Other Medicine Technology:Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 2Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 3Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 4Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 5Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 6Studies Presented at Neurology Conference Highlight Early Efficacy,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron 2Studies Presented at Neurology Conference Highlight Early Efficacy,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron 3Studies Presented at Neurology Conference Highlight Early Efficacy,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron 4
(Date:10/10/2008)...Coach Holly Warlick Teams Up with Legal and Medica...Ever Cancer and Careers Seminar in,Knoxville, KNO...ion of National,Breast Cancer Awareness Month, Can...e joined forces with YWCA Knoxville, The Wellness ...e Holly Warlick, University of Tennessee,women,s b...
(Date:10/10/2008)... The Healthcare Technology Ev... , Exton, PA (PRWEB) Sept...ey Chapters of the national Healthcare Information...forces to bring regional health information techno... conference entitled The Healthcare Technology Evo...
(Date:10/10/2008)...ston, MABoston Medical Center (BMC) has received a...l Institute on Aging (NIA) to fund the Boston Clau...BMC,s Pepper Center is one of only 11 Pepper Cente... Americans Independence Center Program was establi...enator from Florida. During his five decades of pu...
(Date:10/10/2008)...olecular CT adds metabolic information from PET to...gnostic imaging for maximized workflow ...ICH, Germany, Oct. 10 /PRNewswire/ -- Siemens Heal...duces molecular CT, a new concept in,integrated im...d is a,practical solution for today,s shrinking he...
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4
...fare, Indian scientists have been sequencing the g...It is India's first sequencing effort of a complet...several diseases, including tuberculosis and lepro...de from killed Mw drastically reduces treatment ti...
...fer from migraine are more at risk of heart attack...ological condition, of which the most common sympt... Men with migraines were more likely to have high...d cholesterol levels, compared to men who didn't h...
...a bacterium, which is one of the leading cause for...ing cause for blindness globally, is said to be// ...ve imagined. The scientists from Children’s Hospi...ere the first to conclude this with the help of a ...
...two important changes that revolve around prematur...ch-greater ability of medical advances to keep// a...nge that has been noted is the increased rate of p...e births resulting from fertility treatment. A re...
Other Medicine News:Health News:India Finds New Use for an Old Bug 2Health News:India Finds New Use for an Old Bug 3Health News:Newly Identified Strains Of Chlamydia Trachomatis – A Gateway To New Disease 2Health News:Premature Babies- What should be done about them? 2
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
Medicine Products: